Neurobiology of Aging
Volume 28, Issue 4 , Pages 555-567 , April 2007

Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons

  • P. Rey

      Affiliations

    • Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
    • ,
  • A. Lopez-Real

      Affiliations

    • Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
    • ,
  • S. Sanchez-Iglesias

      Affiliations

    • Laboratory of Neurochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
    • ,
  • A. Muñoz

      Affiliations

    • Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
    • ,
  • R. Soto-Otero

      Affiliations

    • Laboratory of Neurochemistry, Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
    • ,
  • J.L. Labandeira-Garcia

      Affiliations

    • Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain
    • Corresponding Author InformationCorresponding author at: Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain. Tel.: +34 981563100; fax: +34 981547078.

Received 8 March 2005 ,Revised 20 February 2006 ,Accepted 27 February 2006.

References 

  1. Allen AM, MacGregor DP, Chai SY, Donnan GA, Kaczymarzyk S, Richardson K, et al. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann Neurol. 1992;32:339–344
  2. Allen AM, Moeller I, Jenkins A, Zhuo J, Aldred GP, Chai SY, et al. Angiotensin receptors in the nervous system. Brain Res Bull. 1998;47:17–18
  3. Basso N, Paglia N, Stella I, Cavanagh EMV, Ferder L, Lores-Arnaiz MR, et al. Protective effect of the inhibition of the renin–angiotensin system on ageing. Regul Pept. 2005;128:247–252
  4. Benarroch E, Schmeichel AM. Immunohistochemical localization of angiotensin type 1 receptor in human hypothalamus and brainstem. Brain Res. 1998;812:292–296
  5. Benzie IFF, Tomlinson B. Antioxidant power of angiotensin-converting enzyme inhibitors in vitro. Br J Clin Pharmacol. 1998;45:168–169
  6. Borawska MH, Kucharewicz G, Wisniewski K. The role of dopamine in the facilitatory effect of angiotensin II on impaired learning in rats chronically treated with ethanol. Psychopharmacology. 1988;96:500–504
  7. Brown DC, Steward LJ, Ge J, Barnes NM. Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo. British J Pharmacol. 1996;118:414–420
  8. Brownfield MS, Reid IA, Ganten D, Ganong WF. Differential distribution of immunoreactive angiotensin and angiotensin-converting enzyme in rat brain. Neuroscience. 1982;7:1759–1769
  9. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ Res. 2005;96:818–822
  10. Cavanagh E, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, et al. Enalapril and losartan attenuate mitochondrial dysfunction in aged rats. FASEB J. 2003;1096–1098
  11. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Islam S, Welch WJ, et al. Effect of Ang II type 1 and 2 receptors on oxidative stress, renal NAD(P)H oxidase, and SOD expresión. Am J Physiol Regu Integr Comp Physiol. 2003;285:R117–R124
  12. Chai SY, Johnston CL. Tissue distribution of angiotensin converting enzyme. In:  Larag JH,  Brenner BM editor. Hypertension: pathophysiology, diagnosis and management. New York: Raven Press; 1995;p. 1683–1693
  13. Chai SY, McKenzie JS, McKinley MJ, Mendelsonhn FAO. Angiotensin converting enzyme in human basal forebrain and midbrain visualized by in vitro autoradiography. J Comp Neurol. 1990;291:179–194
  14. Chai SY, Mendelsohn FAO, Paxinos G. Angiotensin converting enzyme in rat brain visualized by quantitative in vitro autoradiography. Neuroscience. 1987;20:615–627
  15. Daubert DL, Meadows GG, Wang JH, Sanchez PJ, Speth RC. Changes in angiotensin II receptors in dopamine-rich regions of the mouse brain with age and ethanol consumption. Brain Res. 1999;816:8–16
  16. Dogan DM, Sumners C, Broxson CS, Clark N, Tümer N. Central angiotensin II increases biosynthesis of tyrosine hydroxylase in the rat adrenal medulla. Biochem Biophys Res Commun. 2004;313:623–626
  17. Gao HM, Liu B, Hong JS. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J Neurosci. 2003;23:6181–6187
  18. Gao HM, Hong JS, Zhang W, Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J Neurosci. 2003;23:1228–1236
  19. Gao HM, Liu B, Zhang W, Hong JS. Synergistic dopaminergic neurotoxicity of MPTP and inflamogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 2003;17:1957–1959
  20. Ge J, Barnes NM. Alterations in angiotensin AT1 and AT2 receptor subtype levels in brain regions from patients with neurodegenetative disorders. Eur J Pharmacol. 1996;297:299–306
  21. Gendron L, Payet MD, Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation: from observations to mechanisms. J Mol Endocrinol. 2003;31:359–372
  22. Glinka Y, Tipton KF, Youdim MBH. Mechanism of mitochondrial respiratory complex I by 6-hydroxydopamine and its prevention by desferrioxamine. Eur J Pharmacol. 1998;351:121–129
  23. Griendling KK, Sorescu D, Ushio-Fukai M. NADPH oxidase. Role in cardiovascular biology and disease. Circ Res. 2000;86:494–501
  24. Gundersen HJG, Bendsen TF, Korbo L, Marcussen N, Moller A, Nielsen K. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APIMS. 1988;96:379–394
  25. Ichiki T, Takeda K, Tokunou T, Funakoshi Y, Ito K, Iino N, et al. Reactive species-mediated homologous downregulation of angiotensin II type 1 receptor mRNA by angiotensin II. Hypertension. 2000;37:535–540
  26. Intebi AD, Flaxman MS, Ganong WF, Deschepper CF. Angiotensinogen production by rat astroglial cells in vitro and in vivo. Neuroscience. 1990;34:545–554
  27. Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MBH. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm. 1995;46:297–314
  28. Jenkins TA, Chai SY, Howells DW, Mendelsohn FAO. Intrastriatal angiotensin II induces turning behaviour in 6-hydroxydopamine lesioned rats. Brain Res. 1995;691:213–216
  29. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol. 2003;53:S26–S38
  30. Kim AM, Shin K-S, Chung Y-B, Jung KW, Cha CI, Shin DH. Immunohistochemical study of p47Phox and gp91Phox distributions in rat brain. Brain Res. 2005;1040:178–186
  31. Kimura S, Zhang G-X, Nishiyama A, Shokoji T, Yao L, Fan Y-Y, et al. Mitochondria-derived reactive oxygen species and vascular MAP kinases. Comparison of angiotensin II and diazoxide. Hypertension. 2005;45:438–444
  32. Konings CH, Kuiper MA, Bergmans PL, Grijpma AM, van Kamp GJ, Wolters EC. Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin Chim Acta. 1994;23:101–106
  33. Kumar R, Agarwal AK, Seth PK. Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem. 1995;64:1703–1707
  34. Kusaka I, Kusaka G, Zhou C, Ishikawa M, Nanda A, Granger DN, et al. Role of AT1 receptors and NAD(P)H oxidase in diabetes-aggravated ischemic brain injury. Am J Physiol Heart Circ Physiol. 2004;286:H2442–H2451
  35. Lebrun CJ, Mollenhoff E, Bao G, Culman J, Unger T. Angiotensin II induces the expression of c-fos mRNA in the central nervous system of the rat. Clin Exp Hypertens. 1995;17:877–893
  36. Lee J, Adachi K, Gionhaku N, Fujita S, Uchida T, Gerstner GE, et al. Evidence that angiotensin II enhances apomorphine-induced jaw movements via AT1 receptors in the ventrolateral striatum: studies by magnet-sensing system in freely moving rats. Meth Find Exp Clin Pharmacol. 2004;26:195–199
  37. Lenaz G. Role of mitochondria in oxidative stress and ageing. Biochim Biophys Acta. 1998;1366:53–67
  38. Lenkei Z, Palkovits M, Corvol P, Llorens-Cortes C. Expression of angiotensin type-1 (AT1) and type 2 (AT2) receptor mRNAs in the adult rat brain: a functional neuroanatomical review. Front Neuroendocrinol 18:383–439.
  39. Lin J-J, Yueh K-C, Chang D-C, Lin S-Z. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson's disease. J Neurol Sci. 2002;199:25–29
  40. Liu YH, Yang XP, Mehta D, Bulagannawar M, Scicli GM, Carretero OA. Role of kinins in chronic heart failure and in the therapeutic effect of ACE inhibitors in kinogen-deficient rats. Am J Physiol Heart Circ Physiol. 2000;278:H507–H514
  41. Lopez-Real A, Rey P, Soto-Otero R, Mendez-Alvarez E, Labandeira-Garcia JL. Angiotensin-converting enzyme inhibitors reduce oxidative stress and protect dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J Neurosci Res. 2005;81:865–873
  42. Lopez-Real A. Influencia del sistema renina-angiotensina (RAS) sobre la degeneracion del sistema nigroestriatal dopaminergico inducida por 6-OHDA. In: Analisis experimental de nuevas estrategias terapeuticas para la enfermedad de Parkinson. Ph. D. Thesis, University of Santiago de Compostela, Spain; 2003, p. 173–87.
  43. Lou M, Blume A, Zhao Y, Gohlke P, Deuschl G, Herdegen T, et al. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J Cereb Blood Flow Metab. 2004;24:536–547
  44. Lynch KR, Hawelu-Johnson CL, Guyenet PG. Localization of brain angiotensinogen mRNA by hybridization histochemistry. Mol Brain Res. 1987;2:149–158
  45. Markwell MAK, Haas SM, Bieber LL, Tolbert NE. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 1978;87:206–210
  46. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, et al. The brain reenin–angiotensin system: location and physiological roles. Int J Biochem Cell Biol. 2003;35:901–918
  47. Mendelsohn FAO, Jenkins TA, Berkovic SF. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat. Brain Res. 1993;613:221–229
  48. Münzel T, Keany JF. Are ACE inhibitors a “magic bullet” against oxidative stress?. Circulation. 2001;104:1571–1577
  49. Noh KM, Koh JY. Induction and activation by zinc of NADH oxidase in cultured cortical neurons and astrocytes. J Neurosci. 2000;20:RC111;(1–5)
  50. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1986;
  51. Przedborski S, Jackson-Lewis V. Experimental developments in movement disorders: uptake on proposed free radical mechanisms. Curr Opin Neurol. 1998;11:335–339
  52. Quinlan JT, Phillips MI. Immunoreactivity for angiotensin II-like peptide in the human brain. Brain Res. 1981;205:212–218
  53. Rodriguez M, Barroso-Chinea P, Abdala P, Obeso J, Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp Neurol. 2001;169:163–181
  54. Rodriguez-Pallares J, Quiroz CR, Parga JA, Guerra MJ, Labandeira-Garcia JL. Angiotensin II Increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur J Neurosci. 2004;20:1489–1498
  55. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells. Protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Artrioscler Thromb Vasc Biol. 2002;22:1845–1851
  56. Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Suzuki Y, Mezzano S, et al. Role of the renin–angiotensin system in vascular diseases. Expanding the field. Hypertension. 2001;38:1382–1387
  57. Serrano F, Kolluri NS, Wientjes FB, Card JP, Klann E. NADPH oxidase immunoreactivity in the mouse brain. Brain Res. 2003;998:193–198
  58. Simonnet G, Giorguieff-Chesselet MF, Carayon A, Bioulac B, Cesselin F, Glowinski J, et al. Angiotensin II and the nigrostriatal system. J Physiol. 1981;77:71–79
  59. Sohn HY, Raff U, Hoffmann A, Gloe T, Heermeier K, Galle J, et al. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br J Pharmacol. 2000;131:667–672
  60. Soto-Otero R, Méndez-Álvarez E, Hermida-Ameijeiras A, Muñoz-Patiño A, Labandeira-García JL. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J Neurochem. 2000;74:1605–1612
  61. Stornetta RL, Hawelu-Johnson CL, Guyenet PG, Lynch KR. Astrocytes synthesize angiotensinogen in brain. Science. 1988;242:1444–1446
  62. Touyz RM. Reactive oxygen species and angiotensin II signaling in vascular cells—implications in cardiovascular disease. Braz J Med Biol Res. 2004;37:1263–1273
  63. Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, et al. Angiotensin receptors. J Hypertens. 1996;14(Suppl 5):S95–S103
  64. Van Muiswinkel FL, de Vos RAI, Bol JGJM, Andringa G, Jansen Steur ENH, Ross D, et al. Expression of NAD(P)H:quinine oxidoreductase in the normal and Parkinsonian substantia nigra. Neurobiol Aging. 2004;25:1253–1262
  65. Wang G, Anrather J, Huang J, Speth RC, Pickel V, Iadecola C. NADPH oxidase contributes to angiotensin II signalling in the nucleus tractus solitarius. J Neurosci. 2004;24:5516–5524
  66. West MJ, Slomianka L, Gundersen HJG. Unbiased stereological estimation of the total number of neurons of the rat hippocampus using the optical fractionator. Anat Rec. 1991;231:482–497
  67. Zalba G, San Jose G, Moreno MU, Fortuño MA, Fortuño A, Beaumont FJ, et al. Oxidative stress in arterial hypertension. Role of NADPH oxidase. Hypertension. 2001;38:1395–1399

PII: S0197-4580(06)00084-4

doi: 10.1016/j.neurobiolaging.2006.02.018

Neurobiology of Aging
Volume 28, Issue 4 , Pages 555-567 , April 2007

Article Tools

* Image Usage & Resolution